Priority Partners 7231 Parkway Drive, Suite 100 Hanover, MD 21076



Prior Authorization

JOHNS HOPKINS HEALTH PLANS (MEDICAID)

Non-Formulary Exception - Priority Partners

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Johns Hopkins Health Plans at **1-410-424-4607**. Please contact Johns Hopkins Healthcare at **1-888-819-1043** with questions regarding the Prior Authorization process.

Please contact Johns Hopk	process.						
When conditions are met, we will authorize the coverage of Non-Formulary Exception – Priority Partners.							
Drug Name (select from lis	st of drugs shown	n)					
Other, Please specify							
Quantity	Frequency		Strength				
Route of Administration		Expected Length o	f Therapy				
Patient Information							
Patient Name:							
Patient ID:							
Patient Group No.:							
Patient DOB:							
Patient Phone:							
Prescribing Physician							
Physician Name:							
Physician Phone:			•				
Physician Fax:			•				
Physician Address:			•				
City, State, Zip:			•				
Diagnosis:		ICD Code:					
Comments:							
Please circle the appropriate a	answorfor oach guo	ection					
			V N				
Is the requested product being used for an FDA-approved Y N indication OR an indication supported in the compendia of							
current literature (examples: AHFS, Micromedex, current							
	accepted guidelines)?						
[If no, then no further questions.]							
	2. Does the prescribed dose and quantity fall within the FDA- Y N						
approved labeling or within dosing guidelines found in the							
compendia of current literature? [If no, then no further questions.]							

3.	Is the request for a combination product for which individual components are available at similar doses on formulary?	ΥN	
	[If no, then skip to question 5.]		
4.	Has the patient had a trial and failure of the separate individual components due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	Y N	
	[Note: Documentation must be provided.]		
	[If no, then no further questions.]		
5.	Is the request for a brand name product that has a generic available on formulary?	ΥN	
	[If no, then skip to question 7.]		
6.	Has the patient had a trial and failure of the generic agent due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	ΥN	
	[Note: Documentation must be provided.]		
	[If no, then no further questions.]		
7.	Is the request for a drug with an available alternative dosage form for the same active ingredient on formulary?	ΥN	
	[If no, then skip to question 9.]		
8.	Is there a clinical reason why the patient is unable to take an applicable alternative formulary dosage form based on the patient's condition (e.g. age, indication)?	ΥN	
	[Note: Documentation must be provided.]		
	[If no, then no further questions.]		
9.	Is the patient unable to take the required number of formulary alternatives for the given diagnosis due to a trial and inadequate treatment response or intolerance or an expected adverse reaction or contraindication? (Requirement: 3 in a class with 3 or more alternatives, 2 in a class with 2 alternatives, or 1 in a class with only 1 alternative.)	ΥN	
	[Note: Documentation must be provided.]		
	[If yes, then no further questions.]		
10.	Is the patient a new Plan enrollee (less than 3 months since enrollment), and has a medical history of using the requested medication?	ΥN	
	[Note: Documentation must be provided.]		

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is

available for review if requested by the claims p	rocessor, the health plan	sponsor, or, if applicable a
state or federal regulatory agency.		

Prescriber (Or Authorized) Signature and Date